According to filings with the U.S. Securities and Exchange Commission, Endeavor Biomedicines is raising up to $132,583,908.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, John Hood played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Endeavor Biomedicines
With advances in next-generation sequencing and molecular profiling, we now have the tools to uncover the genetic culprits of disease. We can go after targets and indications we were not scientifically capable of investigating in the past. And we can finally bring patients best-in-class medicines across a spectrum of indications that target the core drivers of disease making a significant impact even in terminal conditions. At Endeavor BioMedicines, we are pursuing novel science and developing precision medicines. We combine advancements in technology with insights into the causes of disease to develop best-in-class medicines with the potential to treat the most severe health conditions, including cancer and fibrosis.

To learn more about Endeavor Biomedicines, visit http://www.endeavorbiomedicines.com/

Contact:
John Hood, Chief Executive Officer
858-537-1700
https://www.linkedin.com/in/john-hood-2590a62/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.